Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 5 |
| List of Tables | 5 | 1 |
| List of Figures | 6 | 1 |
| Introduction | 7 | 1 |
| Global Markets Direct Report Coverage | 7 | 1 |
| Polycystic Kidney Disease Overview | 8 | 1 |
| Therapeutics Development | 9 | 2 |
| Pipeline Products for Polycystic Kidney Disease Overview | 9 | 1 |
| Pipeline Products for Polycystic Kidney Disease Comparative Analysis | 10 | 1 |
| Polycystic Kidney Disease Therapeutics under Development by Companies | 11 | 1 |
| Polycystic Kidney Disease Therapeutics under Investigation by Universities/Institutes | 12 | 1 |
| Polycystic Kidney Disease Pipeline Products Glance | 13 | 3 |
| Late Stage Products | 13 | 1 |
| Clinical Stage Products | 14 | 1 |
| Early Stage Products | 15 | 1 |
| Polycystic Kidney Disease Products under Development by Companies | 16 | 1 |
| Polycystic Kidney Disease Products under Investigation by Universities/Institutes | 17 | 1 |
| Polycystic Kidney Disease Companies Involved in Therapeutics Development | 18 | 12 |
| Angion Biomedica Corp. | 18 | 1 |
| Aptevo Therapeutics Inc | 19 | 1 |
| DiscoveryBiomed, Inc. | 20 | 1 |
| Endocyte, Inc. | 21 | 1 |
| IC-MedTech, Inc. | 22 | 1 |
| Ipsen S.A. | 23 | 1 |
| Kadmon Corporation, LLC | 24 | 1 |
| ManRos Therapeutics | 25 | 1 |
| Metabolic Solutions Development Company, LLC | 26 | 1 |
| NovaTarg Therapeutics, Inc | 27 | 1 |
| Otsuka Holdings Co., Ltd. | 28 | 1 |
| XORTX Pharma Corp. | 29 | 1 |
| Polycystic Kidney Disease Therapeutics Assessment | 30 | 10 |
| Assessment by Monotherapy Products | 30 | 1 |
| Assessment by Combination Products | 31 | 1 |
| Assessment by Target | 32 | 2 |
| Assessment by Mechanism of Action | 34 | 2 |
| Assessment by Route of Administration | 36 | 2 |
| Assessment by Molecule Type | 38 | 2 |
| Drug Profiles | 40 | 33 |
| (ascorbic acid + menadione) Drug Profile | 40 | 2 |
| ANG-3070 Drug Profile | 42 | 1 |
| CIM-2 Drug Profile | 43 | 1 |
| CR-8 Drug Profile | 44 | 1 |
| DBM-43H11 Drug Profile | 45 | 1 |
| Drugs for Polycystic Kidney Disease Drug Profile | 46 | 1 |
| EC-0371 Drug Profile | 47 | 1 |
| JP-153 Drug Profile | 48 | 1 |
| lanreotide acetate Drug Profile | 49 | 4 |
| menadione sodium bisulfite Drug Profile | 53 | 1 |
| MSDC-0160 Drug Profile | 54 | 3 |
| MSDC-0602 Drug Profile | 57 | 2 |
| oxypurinol Drug Profile | 59 | 1 |
| pyrimethamine Drug Profile | 60 | 1 |
| Small Molecule to Inhibit EnaC and CFTR for Cystic Fibrosis, Diarrhea and Autosomal Dominant Polycystic Kidney Disease Drug Profile | 61 | 1 |
| Small Molecules to Activate AMPK for Polycystic Kidney Disease Drug Profile | 62 | 1 |
| Small Molecules to Activate Somatostatin Receptor Type 4 for Polycystic Kidney Disease, Acromegaly and Neuroendocrine Tumors Drug Profile | 63 | 1 |
| Small Molecules to Inhibit Hsp90 for Polycystic Kidney Disease Drug Profile | 64 | 1 |
| STA-2842 Drug Profile | 65 | 1 |
| tesevatinib tosylate Drug Profile | 66 | 3 |
| TNFR x TWEAKR Drug Profile | 69 | 1 |
| tolvaptan Drug Profile | 70 | 3 |
| Polycystic Kidney Disease Dormant Projects | 73 | 1 |
| Polycystic Kidney Disease Discontinued Products | 74 | 1 |
| Polycystic Kidney Disease Product Development Milestones | 75 | 11 |
| Featured News &Press Releases | 75 | 1 |
| Jan 11, 2016: Scottish Medicines Consortium Issues Positive Advice For First Ever Treatment For Autosomal dominant polycystic kidney disease | 75 | 1 |
| Nov 02, 2015: Kadmon to Present Clinical Data on Tesevatinib for the Treatment of Polycystic Kidney Disease at ASN's Kidney Week 2015 | 76 | 1 |
| May 28, 2015: Otsuka s JINARC the First-Ever Treatment Approved in Europe for Adults Living with ADPKD, a Chronic Genetic Kidney Disease | 76 | 1 |
| Apr 14, 2015: DiscoveryBioMed is developing a novel and unprecedented dual action small molecule monotherapy for all cystic fibrosis (CF) patients and for other chronic larger market or rare lung and vascular diseases | 77 | 1 |
| Mar 18, 2015: Metabolic Solutions Development Company Highlights Plans for MSDC-0602 in NASH and Polycystic Kidney Disease | 78 | 1 |
| Feb 27, 2015: CHMP Recommends JINARC (Tolvaptan) for Approval in EU: The First Pharmaceutical Treatment for Autosomal Dominant Polycystic Kidney Disease | 79 | 1 |
| Feb 26, 2015: First-Ever Treatment Approved in Canada for Adults Living with ADPKD, a Life-Threatening Kidney Disease | 79 | 2 |
| Sep 15, 2014: DiscoveryBioMed Awarded A Dual SBIR Awards For Drug Discovery, Validation, Optimization And Development For Autosomal Dominant Polycystic Kidney Disease, The Leading Genetic Cause Of Dialysis And Transplantation Worldwide | 81 | 1 |
| Jun 19, 2014: Kadmon Corporation Initiates Phase 2a Portion of KD020 Study in Autosomal Dominant Polycystic Kidney Disease | 82 | 1 |
| Jun 11, 2014: Otsuka Pharmaceutical Initiates Phase 3 Clinical Trial Of Tolvaptan In Patients With Autosomal Dominant Polycystic Kidney Disease | 82 | 1 |
| May 23, 2014: Launch in Japan of Samsca 30 mg Tablet Formulation for Patients With Autosomal Dominant Polycystic Kidney Disease, an Orphan Disease | 83 | 1 |
| Mar 24, 2014: Otsuka Pharmaceutical's Samsca Approved in Japan as the World's First Drug Therapy for ADPKD, a Rare Kidney Disease | 83 | 1 |
| Dec 27, 2013: European Medicines Agency Accepts Otsuka's Marketing Authorisation Application for Tolvaptan, an Investigational Compound for Autosomal Dominant Polycystic Kidney Disease | 84 | 1 |
| Aug 29, 2013: Otsuka Receives Complete Response Letter from U.S. Food and Drug Administration for Tolvaptan for Use in Patients with Autosomal Dominant Polycystic Kidney Disease | 84 | 1 |
| Aug 05, 2013: U.S. Food and Drug Administration s Cardiovascular and Renal Drugs Advisory Committee Recommends Not to Approve Otsuka Pharmaceutical s Tolvaptan for Use in Autosomal Dominant Polycystic Kidney Disease | 85 | 1 |
| Appendix | 86 | 2 |
| Methodology | 86 | 1 |
| Coverage | 86 | 1 |
| Secondary Research | 86 | 1 |
| Primary Research | 86 | 1 |
| Expert Panel Validation | 86 | 1 |
| Contact Us | 86 | 1 |
| Disclaimer | 87 | 1 |
